-
Featured Authors
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
House Patent Reform Bill Filed – Document Link
The House Patent Reform Bill has been filed. The House Judiciary Committee also held a hearing on the Senate Bill and submitted testimony is available. Stay tuned for BIO’s press release on the House Patent Bill.
Coalition Urges Enactment of Patent Reform Legislation to Drive Job Growth and Innovation
Coalition Urges Enactment of Patent Reform Legislation to Drive Job Growth and Innovation (March 24, 2011) BIO joined with 97 other manufacturers, scientists, researchers, academic institutions, and businesses to urge the U.S. House of Representatives to enact patent reform into law in order to strengthen our country’s patent system which will help get breakthrough products to market faster, maximizing our opportunities for job growth. Read the letter (120 KB PDF)
Smith To Introduce House Patent Ahead of Next Week’s Hearing
Article from Tech Daily Dose in the National Journal stating: House Judiciary Chairman Lamar Smith, R-Texas, will introduce his own version of patent reform legislation next week, possibly as early as Monday.
BIO’s Amicus Brief: Microsoft v. i4i
The Biotechnology Industry Organization, along with AUTM and CropLife International, filed an amicus brief in the Microsoft v. i4i Supreme Court case. This case is widely viewed as one of the most fundamental and important patent cases to reach the Supreme Court in probably a decade. Most basically, this case is about the level of certainty a jury or judge must have before finding a patent invalid in litigation. Historically, the law has required a high level Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics
Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15. You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
